Giovanni Maifredi

Dr. Giovanni Maifredi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
IAIppazio Cosimo Antonazzo
Ippazio Cosimo Antonazzo
CFCarla Fornari
Carla Fornari
DRDavide Rozza
Davide Rozza
Sara ContiSara Conti
Sara Conti
RPRaffaella di Pasquale
Raffaella di Pasquale
GMGiampiero Mazzaglia
Giampiero Mazzaglia
Previous studies ruled out the benefits of azithromycin for treatment of patients with COVID-19 who are hospitalized. However, the effects of azithromycin for treatment of patients with positive SARS-CoV-2 test results in the community remains a matter of debate. This study aimed to assess whether azithromycin, when used in subjects with positive test results for SARS-CoV-2, is associated with a reduced risk of hospitalization, in-hospital COVID-19 outcomes, and death. Two study cohorts were selected. Cohort A included subjects with positive test results for SARS-CoV-2 between February 20, 2020 and December 10, 2020; cohort B included subjects infected with SARS-CoV-2 and hospitalized between February 20, 2020 and December 31, 2020. We compared the risk of hospitalization, intensive care unit access, need for mechanical ventilation, and death in azithromycin users versus nonusers. A clustered Fine-Gray analysis was employed to assess the risk of hospitalization; logistic and Cox regressions were performed to assess the risk of intensive care unit access, mechanical ventilation, and death. In cohort A, among 4861 azithromycin users and 4861 propensity-matched nonusers, azithromycin use was associated with higher risk of hospitalization (hazard ratio [HR] 1.59, 95% confidence interval [CI] 1.45-1.75) compared with nonuse. In cohort B, among 997 subjects selected in both groups, azithromycin use was not significantly associated with intensive care unit access (odds ratio [OR] 1.22, 95% CI 0.93-1.56), mechanical ventilation (OR 1.30, 95% CI 0.99-1.70), 14-day mortality (HR0.88, 95% CI 0.74-1.05), or 30-day mortality (HR 0.89, 95% CI 0.77-1.03). Our findings confirm the lack of benefits of azithromycin treatment among community patients infected with SARS-CoV-2, raising concern on potential risks associated with its inappropriate use.

7 July 2022 in Life
Verified
Journal Article
Open access
PDF file
GMGiovanni Maifredi
Giovanni Maifredi
IIIlaria Izzo
Ilaria Izzo
CGCinzia Gasparotti
Cinzia Gasparotti
CSClaudio Vito Sileo
Claudio Vito Sileo
HGHIV-CoV Group
HIV-CoV Group
EReugenia quiros roldan
eugenia quiros roldan
Italy was dramatically hit by the COVID-19 pandemic, and the province of Brescia was one of the epicenters of the outbreak. Furthermore, Brescia has one of the highest incidences of people living with HIV (PLWH) and a substantial presence of migrants. We conducted a retrospective cohort study involving all citizens connected to the Brescia Health Protection Agency, assessing the SARS-CoV-2 burden, COVID-19 prevalence, and vaccination coverage. A total of 1,004,210 persons were included, 3817 PLWH and 134,492 foreigners. SARS-CoV-2 infection, hospitalizations and death were more frequent among Italians than foreigners. SARS-CoV-2 infections and deaths were more frequent in HIV-uninfected people than in PLWH. PLWH and foreigners were less likely to have a SARS-CoV-2 diagnosis compared to HIV-negative patients. Migrants were more likely to be hospitalized but had a lower risk of death compared to HIV-negative patients. Regarding vaccination, 89.1% of the population received at least one dose of vaccine, while 70.4% of the Italian citizens and 36.3% of the foreigner subjects received three doses of vaccine. Foreigners showed a lower risk of being diagnosed with SARS-CoV-2 but a higher risk of complications. HIV infection was not associated with a higher risk of SARS-CoV-2 severe manifestations compared to the general population. COVID-19 vaccine hesitancy was not different between PLWH and HIV uninfected people, but foreigners were more hesitant.

13 December 2023 in Vaccine
Verified
Journal Article
Closed access
EFEliana Ferroni
Eliana Ferroni
NGNicola Gennaro
Nicola Gennaro
GMGiovanni Maifredi
Giovanni Maifredi
OLOlivia Leoni
Olivia Leoni
FPFrancesco Profili
Francesco Profili
MZManuel Zorzi
Manuel Zorzi

17 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IAIppazio Cosimo Antonazzo
Ippazio Cosimo Antonazzo
CFCarla Fornari
Carla Fornari
DRDavide Rozza
Davide Rozza
Sara ContiSara Conti
Sara Conti
RPRaffaella Di Pasquale
Raffaella Di Pasquale
Giampiero MazzagliaGiampiero Mazzaglia
Giampiero Mazzaglia
Background: The role of statins among patients with established cardiovascular diseases (CVDs) who are hospitalized with COVID-19 is still debated. This study aimed at assessing whether the prior use of statins was associated with a less severe COVID-19 prognosis. Methods: Subjects with CVDs infected with SARS-CoV-2 and hospitalized between 20 February 2020 and 31 December 2020 were selected. These were classified into two mutually exclusive groups: statins-users and non-users of lipid-lowering therapies (non-LLT users). The relationship between statins exposure and the risk of Mechanical Ventilation (MV), Intensive Care Unit (ICU) access and death were evaluated by using logistic and Cox regressions models. Results: Of 1127 selected patients, 571 were statins-users whereas 556 were non-LLT users. The previous use of statins was not associated with a variation in the risk of need of MV (Odds Ratio [OR]: 1.00; 95% Confidence Intervals [CI]: 0.38–2.67), ICU access (OR: 0.54; 95% CI: 0.22–1.32) and mortality at 14 days (Hazard Ratio [HR]: 0.42; 95% CI: 0.16–1.10). However, a decreased risk of mortality at 30 days (HR: 0.39; 95% CI: 0.18–0.85) was observed in statins-users compared with non-LLT users. Conclusions: These findings support the clinical advice for patients CVDs to continue their treatment with statins during SARS-CoV-2 infection.

Verified
Closed access
GMGiovanni Maifredi
Giovanni Maifredi
MMMichele Magoni
Michele Magoni
MEMichele Ercolanoni
Michele Ercolanoni
MLMarco Lazzeretti
Marco Lazzeretti
NGNicola Gennaro
Nicola Gennaro
GIGruppo di Lavoro Inmp Covid19 e Immigrati
Gruppo di Lavoro Inmp Covid19 e Immigrati

16 February 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
AMAlice Mulè
Alice Mulè
VCVerena Crosato
Verena Crosato
DKDouglas B. Kuhns
Douglas B. Kuhns
LLLuisa LORENZI
Luisa LORENZI
CCClaudia Chirico
Claudia Chirico
LTLina Tomasoni
Lina Tomasoni
Visceral leishmaniasis (VL) is a parasitic zoonosis caused by Leishmania spp. that usually manifests itself in immunocompromised subjects. It is a rare and neglected disease, and it is not endemic in the province of Brescia (Italy). Three cases of human VL occurred in Brescia from October to December 2021 in immunocompetent patients. We evaluated the patients looking for signs of underlying immunodeficiencies and conducted further epidemiological evaluations in the province of Brescia without success. An analysis of the sera levels of the main cytokines involved in the immune response to VL was performed. All patients presented a significant augmentation of CXCL-10, CCL-4, and IL-6. The patients tested during the acute phase showed an elevation of IL-1α, IL-5, IL-10, and IL-12, while in the recovery phase, higher levels of TNF-α and IL-7 were detected. Altogether, a predominant activation of the T-helper-2 pathway emerged during the acute phase of the parasite infection, while the cytokines associated with the T-helper-1 pathway were less represented. This imbalanced immune response to the parasite infection might play a crucial role in the development of VL in immunocompetent patients.